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Simvastatin is commercially available as tablets and compounded capsules in Brazil. Very few reports 
regarding these capsules’ quality, and consequently their efficacy, are available. The pharmaceutical quality 
of 30 batches of 20 mg simvastatin capsules from the market was evaluated by weight determination, 
content uniformity, disintegration (Brazilian Pharmacopeia), assay and dissolution test (USP32 tablet 
monograph). A HPLC method was developed for assay, content uniformity and dissolution test, and 
specifications were also established. Out of the 30 batches evaluated, 29 showed capsule disintegration 
within 45 min and individual weight variation was within ±10% or ±7.5% relative to average weight, 
for ≤ or > 300 mg, respectively. Only 27 batches met dissolution test criteria with values ≥80% of the 
labeled amount in 45 min; 21 batches showed simvastatin content between 90.0-110.0% of the labeled 
amount and 19 batches had at least 9 out of 10 capsules with content uniformity values between 85.0-
115.0% of the labeled amount with RSD≤6.0%. Only 14 of all (30) batches fully met pharmacopeial 
quality standards. The establishment of test conditions and specification parameters for simvastatin 
capsules showed that there are relevant pharmacopeial quality differences between batches compounded 
by different pharmacies. For 53.33% of the tested products hypercholesterolemic treatment efficacy 
may be compromised. 
Uniterms: Compounded simvastatin capsules. Quality control. RP-HPLC.
No Brasil, a sinvastatina está comercialmente disponível na forma de comprimidos e cápsulas manipuladas. 
Poucos relatos estão disponíveis sobre a qualidade e, consequentemente, a eficácia dessas cápsulas. A 
qualidade de 30 lotes de sinvastatina 20 mg cápsulas do mercado foi avaliada através da determinação 
de peso, uniformidade de conteúdo, desintegração (Farmacopéia Brasileira), doseamento e teste de 
dissolução (monografia comprimidos USP32). Método por CLAE foi desenvolvido para o doseamento, 
uniformidade de conteúdo e teste de dissolução; além disso, especificações foram estabelecidas. Dos 30 
lotes avaliados, 29 apresentaram desintegração da cápsula até 45 min e a variação do peso individual 
foi ± 10% ou ± 7,5% em relação ao peso médio, se ≤ ou > 300 mg, respectivamente. Apenas 27 lotes 
preencheram os critérios do teste de dissolução com valores ≥ 80% da quantidade rotulada, em 45 
min, 21 lotes apresentaram conteúdo de sinvastatina entre 90,0-110,0% do valor rotulado e 19 lotes 
apresentaram pelo menos 9 em 10 cápsulas, com valores de uniformidade de conteúdo entre 85,0 -115,0% 
da quantidade rotulada com RSD ≤ 6,0%. Apenas 14 de todos os lotes (30) atenderam completamente os 
padrões de qualidade farmacopéicos. O estabelecimento das condições para os testes e de especificações 
para os parâmetros das cápsulas de sinvastatina mostrou que houve diferenças relevantes na qualidade 
farmacopeica entre os lotes das cápsulas manipuladas por distintas farmácias. A eficácia do tratamento 
hipercolesterolêmico poderia estar comprometida para 53,33% dos produtos testados. 
Unitermos: Sinvastatina. Cápsulas manipuladas. Controle de qualidade. FR-CLAE.
F. D. Marques-Marinho, J. C. C. Zanon, E. Sakurai, I. A. Reis, A. A. Lima, C. D. Vianna-Soares496
INTRODUCTION
Simvastatin (SIM, Figure 1) is a lipid lowering 
agent widely used worldwide for the treatment of hyper-
cholesterolemia and for reducing morbidity and mortality 
associated with chronic heart disease (The 4S, 1994). It is 
commercially available in tablet and capsule dosage forms. 
SIM capsules are manufactured in Brazil by compounding 
pharmacies. 
The pharmaceutical sector reached its most 
dominant in the late 1980s when it became the focus of 
attention from the regulatory agencies (Bertollo, 2008). 
The creation of the National Sanitary Surveillance 
Agency/ANVISA, the Brazilian regulatory authority, 
led to greater concern over health and safety of products, 
health services, production supervision and drug sales 
(Brasil, 1999). In 2000, ANVISA published its first 
resolution act, RDC 33, aimed at achieving harmonization 
in the compounding pharmacies sector (Brasil, 2000). It 
became mandatory to evaluate the compounded products 
by the pharmacies with respect to their physico-chemical 
quality and different characteristics. The pharmacies 
had to adjust to this requirement in order to remain in 
the market, or else shut down. Only six years later, RDC 
33 resolutions was replaced by the more comprehensive 
RDC 214 (Brasil, 2006). Amid much controversy over 
the latter, another regulation RDC 67 was subsequently 
published in 2007 (Brasil, 2007) and later updated with 
the current RDC 87 amendment in 2008 (Brasil, 2008). 
In this scenario, ANVISA quality requirements for 
products and services offered by compounding pharmacies 
increased upon each new RDC release, leading to the 
commercial survival only of those businesses who could 
adapt and comply. Standardized procedures, process 
monitoring, quality management, employee training 
and more rigorous quality control numbered among 
the requirements. A high investment in equipment, 
personnel training and hiring of outsourced services was 
necessary. Not all pharmacies could afford to meet all 
the demands to incorporate changes. Nevertheless, the 
importance of these requirements to share professional 
responsibility and ensure greater health safety for patients 
was acknowledged.
For the last ten years compounding pharmacies 
have been governed by specific legislation, although 
many doubts about product quality, safety and efficacy 
still remain. Quality control is hampered by the absence 
of specific monographs for compounded products, 
leading to a lack of standardization in quality evaluation 
by accredited analysis laboratories for health, as well 
as, by ANVISA (Brasil, 1999a). Despite the prevailing 
limitations in the compounding pharmaceutical field, the 
number of new pharmacies has increased in recent years, 
according to ANVISA and Compounding Pharmacists 
National Association/ANFARMAG data (ANVISA, 
2005). Today, the importance of compounding pharmacies 
in the communities is incontestable. Compounded 
capsules can be dose personalized, less expensive than 
industrialized tablets, and economically more attractive 
for the population. In view of the social importance of 
the sector, the quality of SIM compounded capsules was 
evaluated in the present study given that it can directly 
influence the safety and efficacy of products. 
MATERIAL AND METHODS
Simvastatin USP reference standard (RS, lot I0D382, 
99.4% purity label claim, United States Pharmacopeia, 
Rockville, MD, USA), methanol HPLC grade (Tedia, 
Fairfield, OH, USA), phosphoric acid 85% (Merck, 
Darmstadt, Germany), sodium dodecyl sulphate (SDS; 
Pharmacopéia Ativos Magistrais, Barueri, SP, Brazil), 
sodium hydroxide (J.T. Baker, Phillipsburg, NJ, USA) and 
monobasic sodium phosphate (Vetec, Rio de Janeiro, RJ, 
Brazil) were used as received. Distilled or ultrapurified 
water (Milli-Q-Plus, Millipore, Bedford, MA, USA) was 
used when necessary. 
Simvastatin 20 mg capsule batches were randomly 
acquired (April to July, 2009) from thirty compounding 
pharmacies in regard to site location in different regions 
of Belo Horizonte, southeast of Brazil. Six batches 
were donated and twenty four were purchased in the 
market. During the study, the compounded capsules were 
stored according to labeled instructions and when not 
specified were stored in a dry and fresh place at ambient 
temperature. Batch characteristics (color and size) and 
capsule unit price are described in Table I. 
FIGURE 1 - Simvastatin chemical structure.
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All capsules batches were submitted to weight 
determination, disintegration, content uniformity 
assessments and evaluated according to Brazilian 
Pharmacopeia general methods (Farmacopéia Brasileira, 
1988, 1996). For weight determination, twenty units of 
each batch were individually weighed on an analytical 
microbalance (BP210D, Sartorius, Edgewood, NY, USA). 
The average weight (AW) was calculated along with 
individual capsule variation relative to AW. Specified 
individual variation could be less than ±10% or ±7.5% 
for AW ≤ 300 mg or AW > 300 mg, respectively. If two 
or more units failed to meet the limits, the capsule (n=20) 
contents were removed and their weight was determined 
by mass difference. A maximum of two units outside the 
original range was tolerated, but their variation had to 
be less than double the specified limits. Disintegration 
time was determined using six units from each batch in 
an Erweka disintegrator (ZT3, Heusenstamm, Germany) 
equipped with chronometer and thermostatic bath at 
37±1°C. The disintegration time limit for all capsules to 
completely disintegrate was 45 min. Content uniformity 
was performed on ten units from each batch. SIM was 
individually assayed by developed HPLC method after 
dilution in a 50 mL volumetric flask and successive 
dilution in methanol until SIM 40 mg/mL. Acceptance 
criteria were no more than one unit outside the specified 
limit of 85.0%-115.0% of the labeled amount (LA). 
However, the individual value had to fall within 75.0-
125.0% LA and the relative standard deviation (RSD) had 
to be less than or equal to 6.0%. For assay and dissolution 
test conditions, the USP32 SIM tablet monograph was 
observed (United, 2009). For assay, an adequate SIM 
mass, equivalent to one AW, was accurately weighed 
(triplicate) and successively diluted with methanol 
(filtered, if necessary) in order to obtain SIM 40 mg/mL 
for injection into the chromatograph. The criterion was 
90.0-110.0% LA. The dissolution test (first stage only) was 
performed for six capsule units from each batch (DT80, 
Erweka, Heusenstamm, Germany) with USP apparatus 2 
(paddle) at 75 rpm for 45 min using stainless steel sinkers 
(Flowscience, Cotia, SP, Brazil) to keep the capsules at 
the vessel bottom. Monobasic sodium phosphate at 0.01M 
containing 0.50% SDS, pH adjusted to 7 (40% w/v sodium 
hydroxide), 900 mL, 37±0.5 °C was used as the dissolution 
medium and selected Q value was 75%. Aliquots of 5.0 mL 
were withdrawn from the dissolution vessels, filtered and 
injected into the chromatograph. The requirement for the 
first stage of the dissolution test was that each unit had to 
release at least 80% LA (Q+5%). A validated RP-HPLC 
method developed in-house was used to determine SIM in 
assay, content uniformity and dissolution test on a HP1200 
quaternary pump liquid chromatograph (Agilent, Palo 
Alto, CA, USA) using methanol and 0.1% phosphoric acid 
(80:20 v/v) as mobile phase, at 30°C, 1.5 mL/min, UV/
DAD detection l 238 nm, with automatic injector fitted 
at 10 ml and a C8 endcapped column (250x4 mm, 5 mm, 
Merck, Darmstadt, Germany). All standard and sample 
solutions were filtered through a 0.45 µm filter membrane 
(Minisart RC15 Sartorius, Goettingen, Germany) before 
injection. 
Calibration curves were constructed from SIM 
methanolic solutions (n=3) prepared at 4, 20, 40, 60, 
80 mg/mL for assay/content uniformity and from SIM in 
dissolution medium solutions (n=3) prepared at 2, 10, 18, 
26, 34 mg/mL for the dissolution test. The respective curve 
equations were used to determine SIM in assay/content 
uniformity and the dissolution test. The R statistical 
software was used to evaluate the curve equation model, 
normality and homoscedasticity (a=0.05) by the weighted 
least squares method, Shapiro-Wilk and Levene tests, 
respectively (Souza, Junqueira, 2005). Data were treated 
by studentized residual model in order to remove outliers 
(residues greater than 3.0) where necessary. Intercept, 
correlation coefficients (r) and % RSD were calculated 
and the chromatographic parameters of asymmetry (As), 
retention factor (k) and retention time (t) were observed 
(Green, 1996; Jenke, 1996; Snyder, Kirkland, Glajch, 
1997; United, 2009a). Results were considered significant 
when the corresponding p value was less than 0.05. 
Selectivity was evaluated through peak purity 
analysis by UV/DAD spectra of capsule samples. In 
a repre sentative capsule sample (acquired from the 
university pharmacy, rather than the 30 pharmacies), SIM 
10, 20 and 40 mg correspondent masses were adequately 
diluted to obtain precision evaluation at three levels of 
concentrations: 20, 40, 80 mg/mL (n=3), respectively. 
Accuracy was assessed by recovery of SIM standard (10, 
20, 40 mg, n=3) added to SIM capsule sample solution 
and properly diluted within the linear range (20, 40, 80 
mg/mL). Robustness was assessed by variations in flow 
rate (±0.1 mL/min), methanol ratio (±2%) and temperature 
(±5 °C) using SIM 40 mg/mL (n=5).
RESULTS AND DISCUSSION
The qualitative composition of all donated SIM 
capsule batches were provided by the respective 
pharmacies. Compounded capsule unit price (Table I) 
ranged from US$0.13 to US$0.27 among the pharmacies, 
a cost approximately 5.6% to 11.7%, respectively, of 
Zocor® tablet unit prices (US$2.30). None of the capsule 
batches showed any problems regarding physical aspect.
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A validated RP-HPLC method for SIM determination 
showed adequate selectivity (Ermer, 2001; Shabir, 2003). 
Chromatographic peak purity (≥99.8%) was provided by 
UV/DAD spectra (Figure 2a,b, details).
Satisfactory results were obtained for precision and 
accuracy (Table II) with RSD values less than 2.0% and 
recovery levels between 98.0-102.0%, respectively. The 
HPLC method was shown to be robust, since there was 
no statistical difference by ANOVA (p value>0.05) after 
variation in flow rate (p=0.71), methanol ratio (p=0.06) 
and temperature (p=0.11).
The response-concentration relationship for assay/
content uniformity and dissolution test curves obtained 
by the weighted least squares method was expressed by a 
quadratic and linear equation, respectively. Both curves 
demonstrated adequate normality (Shapiro-Wilk) and 
homoscedasticity (Levene) for p value>0.05. Intercept 
was not significantly different from zero (p value>0.05) 
for the quadratic model for assay/content uniformity. In 
cases of significant p value less than 0.05, the percentage 
of the intercept (relative to the 100% analyte level) up to 
±2% is accepted, as observed in the linear model for the 
dissolution test (Green, 1996; Jenke, 1996). Correlation 
coefficients (r) were greater than 0.999 for SIM assay/
content uniformity curve (Jenke, 1996) or greater than 
0.98 for the SIM dissolution curve (United, 2009a) and in 
both cases, RSD values were less than 2.0% (Jenke, 1996). 
Results of regression analysis are summarized in Table III.
SIM peak eluted with retention factors, k 2.896 
(5.622 min) and 4.613 (5.676 min) (k>2), asymmetry 
factors 0.96 and 1.02 (As<1.2) for assay/content uniformity 
(Figure 2a) and dissolution test, respectively (Figure 2b) 
were appropriate (Snyder, Kirkland, Glajch,1997). 
The weight determination test results for the 
thirty batches are shown in Table IV. Four batches (P12, 
P17, P19 and P20) had to be retested by the removal of 
content, whereas one batch (P19) did not meet the weight 
requirements because it contained more than two units 
(five) with an individual variation greater than 10%AW. 
Hence, P19 batch showed problems with homogeneity 
of powder distribution inside the capsules. For the 
disintegration test, only batch (P4) did not meet the criteria 
because its capsules did not disintegrate at all within 45 
min. The capsules ended swollen and soft suggesting a 
formulation problem, probably related to a high percentage 
(30% w/w) of carboxymethylcellulose (CMC), a gel 
forming agent (Rowe, Sheskey, Quinn, 2009).
For content uniformity (n=30, Table IV), only 
nineteen (63.3%) batches met the requirements of within 
85.0-115.0% LA (87.2-106.3%) and RSD values were less 
than or equal to 6.0 (1.9-6.0%). Ten batches (P4, P10, P12, 
TABLE I – Description of simvastatin 20 mg capsule batches 
acquired from thirty compounding pharmacies 
Pharmacy 
(P)
Capsule 
price (US$)a
Capsule color; 
size
Storage 
conditions
1 Db red/white; 4 NSc
2 D white/white; 1 Also, protect 
from light and 
humidity
3 D green/white; 4 NS
4 D blue/white; 1 NS
5 D green/white; 3 Keep 
refrigerated.
6 D green/white; 4 Keep 
refrigerated.
7 0.20 green/white; 4 NS
8 0.17 transparent; 4 NS
9 0.26 blue/white; 4 Keep in dry 
place
10 0.27 red/white; 3 NS
11 0.25 orange/yellow; 2 NS
12 0.22 green/white; 3 NS
13 0.22 bordeaux/white; 3 Keep well 
closed
14 0.23 blue/white; 3 NS
15 0.17 bordeaux/white; 2 NS
16 0.14 bordeaux/white; 3 NS
17 0.19 dark blue/white; 3 NS
18 0.17 blue/white; 2 Protect from 
heat and 
humidity
19 0.18 green/white; 4 NS
20 0.18 transparent; 3 NS
21 0.13 white; 3 NS
22 0.14 blue/gray; 4 NS
23 0.23 blue/white; 3 NS
24 0.18 blue/white; 3 Protect from 
heat and 
humidity
25 0.23 blue/white; 4 Protect from 
heat and 
humidity
26 0.17 blue/white; 4 NS
27 0.23 green/white; 2 NS
28 0.13 green/white; 4 NS
29 0.15 white; 4 NS
30 0.20 transparent; 4 NS
a: Zocor® 20 mg tablet unit price US$2.30, for comparison. 
Currency conversion BRL to US dollar; b: D, donation; c: NS, 
not specified.
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P18, P19, P21, P22, P27-29) out of eleven, which failed 
the test, had an RSD greater than 6.0% (6.2-19.7%) and 
one batch (P25) had three units below 85.0% LA despite 
having a RSD  lower than 5.0%. These problems related to 
FIGURE 2 - SIM representative chromatograms for (a) assay/content uniformity, detail: SIM UV/DAD spectrum and (b) dissolution 
test, detail peak: purity curves. Chromatographic conditions: C8 endcapped (250x4 mm, 5 mm) 30 °C, l 238 nm, methanol:0.1% 
phosphoric acid (80:20 v/v), 1.5 mL/min, injection volume 10 ml. Dissolution conditions: 0.5% SDS in 0.01 M monobasic sodium 
phosphate pH 7 (900 mL, 37±0.5 °C), paddles, 75 rpm, 45 min.
TABLE II - HPLC precision and accuracy results for SIM 20 mg compounded capsules provided by the university pharmacy 
(chromatographic conditions, Figure 2)
Validation parameters
SIM amount/capsule
SIM, mg (RSD)a
10 20 40
Precision
Intraday (n=3)
Analysts            I 8.7 (1.6) 17.6 (0.9) 34.9 (1.2)
                           I 8.8 (1.3) 17.9 (1.1) 34.2 (0.1)
                           II 8.9 (1.9) 17.5 (1.1) 34.0 (2.0)
Interday (n=9) 8.8 (1.7) 17.7 (1.4) 34.4 (1.7)
Accuracy (n=3)
Standard addition 9.9 (0.8) 19.7 (0.4) 39.4 (0.3)
%Recovery 99.2 98.4 98.6
a: RSD, relative standard deviation.
high %LA variability reflected either inadequate powder 
homogenization or poor capsule powder distribution 
leading to drug content differences between units within 
the same batch. Assay results (Table IV) show that twenty-
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TABLE IV - Quality control test results for thirty batches of simvastatin 20 mg compounded capsules (conditions, Figure 2)
Pharmacy 
(P)
Mean weighta
(mg)
Disintegration timec 
(min)
Content uniformitya 
(%)
Assaya
(%)
Dissolutiona
(%)
1 174.4±1.89 26 91.46±1.98 88.22±0.21 93.66±1.02
2 302.6±2.11 14 95.57±2.74 94.10±0.40 96.71±4.49
3 145.5±1.78 16 92.26±5.89 85.58±0.45 98.40±7.00
4 390.5±2.06 >45 92.11±12.89 99.00±1.80 10.11±14.93
5 190.4±2.84 27 96.17±3.18 95.91±0.63 97.13±4.23
6 152.3±2.87 28 96.77±3.65 92.28±0.28 101.59±2.81
7 159.6±3.01 16 93.60±4.61 93.28±1.17 91.99±3.03
8 140.7±2.10 18 95.51±4.57 96.70±0.35 99.95±4.39
9 148.4±1.94 20 90.26±4.77 87.97±0.70 99.30±5.02
10 167.5±2.43 20 103.71±6.36 97.26±0.19 104.83±3.80
11 263.2±2.16 22 87.25±3.66 88.87±1.16 93.60±3.83
12 194.2±4.77b 15 86.93±10.32 89.05±0.58 94.70±16.94
13 220.8±2.47 26 91.84±1.94 91.78±0.27 86.81±2.04
14 234.7±2.46 20 89.19±2.77 90.93±0.26 94.67±3.40
15 306.5±1.90 18 106.27±3.06 105.37±0.65 109.84±2.48
16 205.4±1.28 19 92.62±2.97 93.49±0.33 96.49±6.15
17 128.6±4.55b 14 96.58±6.05 95.96±0.30 97.63±4.99
18 219.5±4.47 20 98.33±19.67 87.46±0.97 101.85±24.63
19 144.2±4.81b 16 90.94±6.24 95.26±0.84 92.92±5.88
20 176.8±4.46b 12 93.14±4.88 93.09±0.27 98.39±4.69
21 166.9±1.50 19 92.89±11.48 90.74±0.75 97.48±10.95
22 157.7±4.75 26 97.18±16.81 94.25±0.63 105.68±15.17
23 192.6±1.45 12 91.63±2.23 90.83±0.80 89.80±5.84
24 194.6±1.43 24 89.72±3.18 88.96±1.00 98.17±5.83
25 132.3±3.05 16 88.50±4.97 88.03±1.09 92.59±2.08
26 117.9±2.13 13 91.78±3.18 92.49±1.25 96.27±1.88
27 273.6±4.33 15 92.10±8.81 101.91±0.64 96.17±10.39
28 172.4±3.75 16 90.52±8.05 88.23±1.19 91.88±11.94
29 134.9±1.95 17 96.90±11.49 92.26±0.10 100.07±6.46
30 234.6±1.98 22 95.92±1.92 96.52±1.14 100.22±4.79
a: mean ± RSD [(standard deviation/mean)x100]; b: before removal of content; c: maximum time for complete disintegration.
TABLE III – Statistical regression results by ANOVA for SIM assay/content uniformity and dissolution test by HPLC (chromatographic 
conditions, Figure 2)
Parameter Assay/Content uniformitya Dissolution testb
Range (mg/mL) 4-80 2-34
Regression equation y = 0.0122x2+22.1837x-0.1805 y = 21.5099x+4.2288
p-value regression 2.2x10-16 2.2x10-16
%RSD 0.47 0.22
Correlation coefficient, r 0.9999 0.9999
Intercept p valuec 0.79 0.003
Shapiro-Wilk (p value)d 0.97 (0.81) 0.92 (0.26)
Levene (p value)d 0.49 (0.74) 0.24 (0.91)
a: diluent methanol; b: diluent 0.5% SDS in 0.01 M monobasic sodium phosphate (pH 7), c: significant for p value<0.05, d: no 
statistical evidence of problems for p value>0.05.
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one batches (70%) met the criteria 90.0-110.0% LA (90.74 
to 105.37%) and RSD was less than 2.0% (0.2 to 1.8%). 
All nine batches (P1, P3, P9, P11, P12, P18, P24, P25, P28) 
that failed the test showed %LA less than 90.0 but greater 
than or equal to 85.5%. In some cases, the problem was 
due to the fact that a purity correction factor may not have 
been established for the raw material used.
Dissolution test results (Table IV) were evaluated 
according to SIM % average release and RSD values: 
27 batches met the acceptance criteria with individual 
values greater than or equal to 80% LA (20 mg SIM). All 
three batches (P4, P12, P18) that failed the test showed 
high RSD values (14.9, 16.9, 24.6%). Batch P4, whose 
capsules contained a high CMC percentage (30% w/w) 
showed very low drug release (≤12.7%) for all units. 
This suggests a serious formulation problem, leading to 
a large quality discrepancy and hence, drug inefficacy. 
In summary, out of 30, only 14 (46.6%) batches met the 
requirements for all quality control tests, encoded P2, 
P5-8, P13-17, P20, P23, P26, P30. The most common 
problem was related with content uniformity, occurring in 
68.7% of non-approved batches. This finding represents 
a major concern for the regulatory authorities since it is 
related with low quality of powder homogenization and 
its distribution in the capsules, in an essential practice 
in compounding pharmacies. The second most frequent 
problem was observed for SIM assay, which occurred in 
56.2% of non-approved batches. This may possibly be 
explained by the lack or inappropriate use of a correction 
factor due to a raw material with lower purity. Low 
%SIM release after dissolution test occurred in 18.7% 
of non-approved batches. These results are closely 
related to the content uniformity results, since all such 
batches also showed high RSD values greater than 10.3% 
for content uniformity test. Weight determination and 
disintegration problems occurred in isolated batches. 
Therefore, the conditions and acceptance criteria 
established for pharmaceutical control tests applicable 
to SIM compounded capsules are important to evaluate 
the quality of distinct batches traded not only locally, 
but also, nationwide. These tests and their specifications 
have been suggested to devise a SIM capsule monograph, 
as guidance for pharmaceutical quality control of these 
products to be included in the latest edition of the 
Brazilian Pharmacopeia. Although drug compounding 
activities in Brazil have been regulated by ANVISA 
for the last ten years, by means of several acts and their 
updates, content uniformity problems can be easily 
avoided by rigorous quality requirements and personnel 
training. In addition, considering that each batch had 
been acquired by one patient, 53.3% of these individuals 
would have had their treatment compromised due to lack 
of quality compliance.
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